A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection

Trial Profile

A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2016

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms C-EDGE IBLD
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Apr 2016 Results of 2 trials, C-EDGE IBLD and C-EDGE CO-STAR were published in a Merck media release.
    • 16 Apr 2016 According to a Merck media release, results of 2 trials, C-EDGE IBLD and C-EDGE CO-STAR were presented at The International Liver Congress 2016.
    • 02 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top